NEW YORK, June 22, 2026, 10:04 EDT
- Apogee Therapeutics NASDAQ:APGE traded at $132.69, up about 47%, after AbbVie agreed to buy the company for $135.11 a share in cash.
- AbbVie said the deal adds zumilokibart, a late-stage IL-13 antibody for atopic dermatitis, and is expected to close in the third quarter of 2026.
- The stock still sat about 1.8% below the cash offer, leaving a deal spread tied to approval timing, antitrust review and shareholder votes.
Apogee Therapeutics NASDAQ:APGE shares surged on Monday after AbbVie agreed to acquire the biotech company for $10.9 billion in cash, giving the U.S. drugmaker control of a long-acting immunology drug candidate aimed at eczema and asthma. Apogee was recently trading at $132.69, up about 47%, against AbbVie’s $135.11-a-share offer.
The move matters now because Apogee’s lead drug, zumilokibart, is nearing late-stage testing just as large pharmaceutical companies are paying up for pipeline assets that can replace aging blockbusters. AbbVie said Apogee’s portfolio would deepen its immunology business and accelerate its move into respiratory disease.
U.S. markets were open, with Nasdaq regular trading hours running from 9:30 a.m. to 4 p.m. Eastern time after the June 19 Juneteenth closure. The SPDR S&P Biotech ETF, a broad biotech fund, rose about 3.2%, but Apogee’s move was almost entirely deal-driven.
AbbVie Chief Executive Robert A. Michael said the acquisition adds the “science, scale and expertise” needed in complex immune diseases. Apogee CEO Michael Henderson said the deal “positions our programs to reach their full potential.” AbbVie News Center
The strategic read-through is plain: AbbVie is buying dosing convenience as much as a drug. Zumilokibart is being studied as an injection given every three or six months, compared with the every-two-week dosing typical for Dupixent, the blockbuster eczema and asthma drug sold by Sanofi and Regeneron.
RBC Capital Markets analyst Brian Abrahams told Reuters the deal “makes sense” and called AbbVie an ideal buyer to maximize zumilokibart’s potential. He said Apogee had long been viewed as a possible takeover target because of less frequent dosing and the size of the atopic dermatitis market. Reuters
The underwatched part of the trade is the spread. At $132.69, Apogee still traded $2.42 below the cash offer; in merger trading, that gap is the market’s price for waiting and for the chance the deal does not close. The filing shows the transaction needs Apogee shareholder approval and regulatory clearances, and the merger agreement carries matching $381.3 million termination fees in some break scenarios, including a regulatory-failure fee payable by AbbVie.
A second, less obvious catalyst came last month. Apogee had secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences, including a synthetic royalty, a financing structure that gives capital in exchange for future sales payments rather than new shares. That agreement included a change-of-control buyback option for a significant portion of the royalty, a feature that likely made Apogee easier to value for a buyer rather than locking AbbVie into a full future royalty burden.
Clinical data also helped set the floor for the bid. In May, Apogee said a mid-dose of zumilokibart met the main goal in a Phase 2 trial, with 65.9% of patients achieving EASI-75, a common eczema measure showing at least a 75% improvement in disease severity. Dermatology expert Ruth Ann Vleugels said the data showed “significantly fewer injections” than current standard care. Apogee Therapeutics, Inc.
But the risk has not disappeared. The deal is still subject to shareholder and regulatory approval, and zumilokibart remains an experimental drug; late-stage trials can miss, safety signals can emerge, and rivals including Sanofi, Regeneron and Eli Lilly already have scale in inflammatory disease markets. AbbVie also said the transaction would not add to adjusted earnings per share until 2032, which leaves a long runway before the asset must prove itself commercially.
